According to the Zhitong Finance App, Fussen Pharmaceutical (01652) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 114 million (same unit), an increase of 2.49% over the previous year; the loss due to the company's equity holders was RMB 13.6.74 million, a decrease of 40.9% year on year; loss of 1.84 points per share.

According to the announcement, the decline in earnings was mainly due to a decrease in sales of the Group's products.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.